

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

-----

SCHEDULE 13D/A  
(Rule 13d-101)

INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO RULE  
13d-1(a) AND AMENDMENTS THERETO FILED PURSUANT TO RULE 13d-2(a)

(Amendment No. 1)

INTERNATIONAL MUREX TECHNOLOGIES CORPORATION

-----  
(NAME OF ISSUER)

Common Shares

-----  
(TITLE OF CLASS OF SECURITIES)

46005H100

-----  
(CUSIP NUMBER)

Jose M. de Lasa  
Senior Vice President, Secretary  
and General Counsel  
Abbott Laboratories  
100 Abbott Park Road  
Abbott Park, Illinois 60064-3500  
(847) 937-6100

with a copy to:  
Scott J. Davis  
James T. Lidbury  
Mayer, Brown & Platt  
190 South LaSalle Street  
Chicago, Illinois 60603  
(312) 782-0600

-----  
(NAME, ADDRESS AND TELEPHONE NUMBER OF PERSON  
AUTHORIZED TO RECEIVE NOTICES AND COMMUNICATIONS)

April 17, 1998

-----  
(DATE OF EVENT WHICH REQUIRES FILING OF THIS STATEMENT)

If the filing person has previously filed a statement on Schedule 13G to report the acquisition which is the subject of this Schedule 13D, and is filing this schedule because of Rule 13d-1(e), 13d-1(f) or 13d-1(g), check the following box / /

(Continued on following pages)  
(Page 1 of 7 Pages)

1 NAME OF REPORTING PERSONS  
I.R.S. IDENTIFICATION NOS. OF ABOVE PERSONS (ENTITIES ONLY)

AAC Acquisition Ltd. (None)  
Abbott Laboratories (# 36-0698440)

2 CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (a)

(b)

3 SEC USE ONLY

4 SOURCE OF FUNDS

WC

5 CHECK BOX IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED  
PURSUANT TO ITEM 2(d) or 2(e)

6 CITIZENSHIP OR PLACE OF ORGANIZATION

AAC Acquisition Ltd. - British Columbia  
Abbott Laboratories - Illinois

NUMBER OF SHARES	7 SOLE VOTING POWER 0
BENEFICIALLY OWNED BY EACH	8 SHARED VOTING POWER 16,174,704 Common Shares

REPORTING		9 SOLE DISPOSITIVE POWER
PERSON		0
-----		
WITH		10 SHARED DISPOSITIVE POWER
		16,174,704 Common Shares

11 AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

16,174,704 Common Shares

-----

12 CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES  
CERTAIN SHARES

-----

13 PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11)

96.00%

-----

14 TYPE OF REPORTING PERSON

AAC Acquisition Ltd.  
Abbott Laboratories

CO  
CO

---

This Amendment No. 1 on Schedule 13D/A amends the filing persons' Schedule 13D (the "Original Schedule 13D"). All capitalized terms used and not otherwise defined herein shall have the meanings assigned to those terms in the Original Schedule 13D.

ITEM 4. PURPOSE OF THE TRANSACTION

The Offer expired at midnight on April 16, 1998. On April 17, 1998, Purchaser accepted for payment at the Offer Price all of the 16,174,704 Common Shares validly tendered and not previously withdrawn in response to the Offer, including 177,572 Shares tendered pursuant to guaranteed delivery procedures. As a result, Purchaser is the beneficial owner of 96.00% of the outstanding Common Shares and Parent and Purchaser intend to effect the Compulsory Acquisition as promptly as practicable.

Upon Purchaser's acceptance for payment of the Common Shares in the Offer, George Brazier, The Honorable J. Trevor Eyton, O.C., Thomas L. Gavan, M.D., Norbert J. Gilmore, Ph.D, M.D., Jay A. Lefton, Hartland M. MacDougall, CVO, O.C., Stanley. E. Read, Ph.D., M.D. and Victor A. Rice each resigned from the Board of Directors of the Company and Christopher Bleck, Thomas D. Brown, Peter J. O'Callaghan, Jeffrey L. Smith, Gordon T. Warriner and Miles D. White, each a designee of Parent and Purchaser, were elected to the Company's Board of Directors.

ITEM 5. INTEREST IN SECURITIES OF THE ISSUER.

(a) Purchaser is the beneficial owner of 16,174,704 Common Shares which represent 96.00% of the total outstanding Common Shares. Parent is deemed to beneficially own all of the Common Shares beneficially owned by Purchaser.

(b) Parent and Purchaser have the shared power to vote or to direct the vote and to dispose or direct the disposition of 16,174,704 Common Shares.

ITEM 7. MATERIAL TO BE FILED AS EXHIBITS.

Exhibit No.	Description
- - - - -	- - - - -
99(a) (12)	Press Release dated April 17, 1998.

SIGNATURE

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

Dated: April 17, 1998

AAC ACQUISITION LTD.

By: /s/ Thomas D. Brown

-----  
Name: Thomas D. Brown  
Title: Vice President

ABBOTT LABORATORIES

By: /s/ Miles D. White

-----  
Name: Miles D. White  
Title: Executive Vice President

EXHIBIT INDEX

Exhibit No. -----	Description -----
99(a) (12)	Press Release dated April 17, 1998.

-----  
Abbott Laboratories  
Corporate Communications  
Abbott Park, Illinois 60064

FOR IMMEDIATE RELEASE

Media:  
Rhonda Luniak  
(847) 938-9725

Financial Community:  
John Thomas  
(847) 938-2655

ABBOTT LABORATORIES ACQUIRES CONTROL OF INTERNATIONAL MUREX TECHNOLOGIES CORPORATION

ABBOTT PARK, Ill., April 17, 1998 -- Abbott Laboratories announced today that it has acquired control of International Murex Technologies Corporation. Abbott's cash tender offer to purchase all of the outstanding common stock of Murex expired as scheduled at midnight, Eastern Standard Time, on Thursday, April 16, 1998. The tender offer has not been extended.

A total of 16,174,704 shares of Murex common stock were validly tendered and not withdrawn prior to the expiration of the offer, including 177,572 shares subject to guaranteed delivery procedures. Abbott has accepted all of these shares for payment. These shares represent approximately 96 percent of Murex's outstanding shares on a fully diluted basis.

-more-



As the final step of the acquisition process, the remaining shares of Murex will be acquired by an indirect wholly owned subsidiary of Abbott in a compulsory acquisition procedure for \$13 per share. Under this procedure, a formal notice regarding the process for purchasing the remaining shares will be sent to Murex shareholders. Given Abbott's controlling interest in Murex, Abbott will own 100 percent of Murex upon completion of the compulsory acquisition procedure.

Under the terms of Abbott's March 16, 1998, definitive agreement with Murex, Abbott will pay the Murex equity holders approximately \$234 million, net of the exercise price on existing Murex options, for 100 percent of the equity in Murex.

Murex develops, manufactures and markets a wide range of products for the detection, screening and monitoring of infectious diseases and other medical conditions.

Abbott Laboratories is a global, diversified health care company devoted to the discovery, development, manufacture and marketing of pharmaceutical, diagnostic, nutritional and hospital products. The company employs 54,000 people and markets its products in more than 130 countries. In 1997, the company's sales and net earnings were \$11.9 billion and \$2.1 billion, respectively, with basic earnings per share of \$2.72 and diluted earnings per share of \$2.68.

###